文献速递临床试验与 GCP基础与转化研究

地舒单抗治疗与传统治疗对类风湿关节炎患者骨侵蚀进展抑制作用的比较研究:基于HR-pQCT的开放标签随机对照试验研究方案

Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
PubMed 文献 · Trials · 2019-08-13

本研究为开放标签随机平行对照试验,计划纳入44例接受传统合成改善病情抗风湿药(csDMARDs)治疗的类风湿关节炎患者,随机分为继续csDMARDs单药治疗或联合地舒单抗治疗,干预12个月。主要终点为基线至6个月时高分辨率外周定量CT(HR-pQCT)测量的骨侵蚀深度变化,旨在评估地舒单抗在真实世界中对骨侵蚀和骨微结构的抑制作用。

要点

  • 地舒单抗联合csDMARDs对比单用csDMARDs,主要终点为6个月骨侵蚀深度变化。
  • 每6个月行HR-pQCT评估骨侵蚀深度、宽度、体积及骨微结构。
  • 研究计划纳入44例RA患者,干预疗程12个月。

核心结论

  • 研究结果预期为地舒单抗治疗类风湿关节炎的有效性提供有力证据。
  • 通过HR-pQCT还可揭示地舒单抗对骨侵蚀及骨微结构的作用。

研究设计与样本

  • 开放标签、随机、平行组研究,计划纳入44例接受csDMARDs治疗的类风湿关节炎患者。
  • 随机分为继续csDMARDs单药治疗组或csDMARDs联合地舒单抗治疗组,干预12个月。
  • 每6个月进行HR-pQCT检查以精确分析骨侵蚀和骨微结构。

关键数值与推荐

  • 主要终点为基线至6个月时HR-pQCT测量的骨侵蚀深度变化。
  • 重要次要终点包括基线至6个月骨侵蚀宽度和体积变化,以及基线至12个月骨侵蚀深度变化。
  • 骨微结构变化作为探索性终点分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints, causes joint destruction, and leads to physical disability. Advances in the treatment of RA, such as biologic disease-modifying anti-rheumatic drugs (DMARDs), have provided better clinical outcomes, including the achievement of remission for patients with RA, but some patients cannot receive these treatments because of their side effects and high cost, and not all patients achieve remission. Although the efficacy of denosumab, which is a human IgG2 monoclonal antibody with a high affinity for the receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), in the treatment of RA has been reported in clinical trials, the efficacy of denosumab in both preventing joint destruction and improving disease activity has not been evaluated in a real-world setting. METHODS/DESIGN: This open-label, randomized, parallel-group study will compare the continued use of conventional synthetic DMARDs (csDMARDs) alone with the combined use of csDMARDs and denosumab in patients whose RA is treated with csDMARDs. In total, 44 patients with RA will be randomly assigned to receive additional treatment with denosumab or to continue RA treatment without additional denosumab. The duration of the intervention will be 12 months. To analyze bone erosion and bone micro-architecture precisely, high-resolution peripheral quantitative computed tomography (HR-pQCT) will be performed every 6 months. The primary endpoint is changes in the depth of bone erosion as measured by HR-pQCT from baseline to 6 months. Important secondary endpoints are the changes from baseline in the width and volume of bone erosion as measured by HR-pQCT and changes from baseline in the depth of bone erosion at 12 months. Changes in bone micro-architecture will also be analyzed as an exploratory endpoint. DISCUSSION: The results of this study are expected to provide strong evidence regarding the usefulness of denosumab for the treatment of RA. Moreover, by using HR-pQCT, this study will also reveal the effect of denosumab not only on bone erosion but also on bone micro-architecture. TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry as UMIN000030575 on December 26, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Iwamoto N, Sato S, Sumiyoshi R, et al. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT. Trials. 2019. PMID: 31409388. doi:10.1186/s13063-019-3589-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。